Avonex PEN Satisfaction and Patients Experience Clinical Trial (ASPECT)
An Open-Label, Survey-Based, Multicenter Study to Determine Patient Satisfaction With Single-Use Prefilled Avonex® PEN Autoinjector in Multiple Sclerosis Patients
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Medical Center
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- Saint John Regional Hospital
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Newfoundland and Labrador, Canada, A1B 3V6
- MUN Hospital
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 4K4
- Dalhousie MS Research Unit
-
-
Ontario
-
Guelph, Ontario, Canada, N1H 4J4
- Norfolk Medical Clinic
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Gatineau, Quebec, Canada, J9J 0A5
- Clinique Neuro-Outaouais
-
Greenfield Park, Quebec, Canada, J4V 2J2
- Neuro Rive-Sud
-
Quebec City, Quebec, Canada, G1M 2S8
- IRDPQ
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Must give written informed consent. If required by local law, candidates must also authorize the release and use of Protected Health Information (PHI)
- Must be 18 to 65 years old, inclusive, at the time of informed consent
- Must be on AVONEX PS for at least 12 consecutive weeks
- Must be self-injecting AVONEX PS at the vastus lateralis site without any help, with or without use of Personal Injector
- Must be prescribed AVONEX PEN as per local labeling (Product Monograph) and enrolled in MS Alliance
- Must be able to physically demonstrate use of the Autoinjector device and be able to self-administer the injections
- Must be able to understand and comply with the protocol
Exclusion Criteria:
- Female subjects considering becoming pregnant while in the study or who are currently pregnant or breast-feeding
- Other unspecified reasons that, in the opinion of the Investigator or Sponsor, make the subject unsuitable for enrollment
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Patient satisfaction
Time Frame: 2 months
|
2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ease of use grading scale
Time Frame: 2 months
|
2 months
|
|
Autoinjector instructions grading scale
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AVX-CAN-11-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.